Ergothioneine Anti-Inflammatory: The Research Evidence

Ergothioneine & Inflammation

1,000× higher concentration in immune cells

Ergothioneine concentrates inside immune cells at up to 1,000 times its level in blood plasma via a dedicated transporter, making it the only dietary antioxidant with targeted delivery to the cells that drive inflammation.

Gründemann et al., PNAS, 2005

3

inflammation signaling pathways blocked (NF-κB, MAPK, PI3K/AKT)

2025

most recent disease model: psoriasis macrophage repolarization

CRP ↓

direction of change in the only published human supplementation trial

Gründemann et al., PNAS, 2005

View as image ↗

Ergothioneine reduces inflammation, and the mechanism is more direct than most people expect. In 2010, researchers added ergothioneine to human monocytes and triggered those cells with standard inflammatory stimuli. The protein complex that switches on inflammatory gene expression, called NF-κB, failed to activate. The inflammatory messenger IL-8 dropped. The enzyme responsible for producing the potent inflammatory signal IL-1β was also blocked.^[1] This was not a passive antioxidant scavenging reactive molecules after the fact. Ergothioneine interfered with the signaling that starts inflammation in the first place.

That 2010 experiment opened a line of ergothioneine anti-inflammatory research that now runs through psoriasis models, heart tissue, aging brain tissue, and a human clinical pilot trial. For a full overview of what ergothioneine is and why the human body has a dedicated cellular transporter for it, see the ergothioneine overview. This article covers the anti-inflammatory evidence: which pathways are affected, where the evidence was gathered, and where it still has gaps.

The short picture: three signaling pathways are suppressed, the effect has been replicated across multiple tissue types, and one small human trial found inflammation biomarkers trending downward after supplementation. The mechanistic case is coherent and growing, but most of the evidence remains preclinical.

The 2010 Experiment That First Proved Ergothioneine Directly Blocks the Inflammation Switch

Before 2010, ergothioneine's anti-inflammatory reputation rested on indirect logic. Reactive oxygen species drive inflammation. Ergothioneine neutralizes reactive oxygen species. Therefore ergothioneine should reduce inflammation. The mechanism was inferred, not demonstrated.

Cheah and colleagues tested it directly using human monocyte cultures.^[1] Monocytes are front-line immune cells that detect inflammatory triggers and launch the initial alarm response. When exposed to hydrogen peroxide or TNF-α, they activate NF-κB, a protein complex that acts as the master switch for inflammatory gene expression. Once active, NF-κB moves into the cell nucleus, switches on hundreds of pro-inflammatory genes, and initiates the release of cytokines including IL-8, which recruits additional immune cells to amplify the response. Caspase-1, the enzyme that converts stored inactive IL-1β into its active, potent form, also turns on.

With ergothioneine present, NF-κB activation was blocked. IL-8 release dropped. Caspase-1 was inhibited. The result held against both triggers: the oxidative signal (hydrogen peroxide) and the cytokine signal (TNF-α).

What this established matters beyond the specific cells tested. Blocking NF-κB early in the signaling chain doesn't just reduce one cytokine. It dampens the entire downstream inflammatory program, because NF-κB controls the expression of most of the major pro-inflammatory genes simultaneously. And blocking caspase-1 limits IL-1β, one of the most potent individual inflammatory signals in human biology. Every subsequent mechanistic study on ergothioneine's anti-inflammatory action has built on this 2010 foundation.

Why Ergothioneine Reaches Immune Cells That Other Antioxidants Cannot

Most dietary antioxidants distribute roughly in proportion to blood concentration. Vitamin C, vitamin E, and polyphenols enter tissues and cells without a dedicated transport mechanism. Ergothioneine takes a different route.

In 2005, Dirk Gründemann and colleagues at the University of Cologne identified OCTN1, the body's dedicated transporter for ergothioneine.^[4] They characterized SLC22A4, the gene encoding OCTN1, as a high-affinity transporter with essentially one substrate: ergothioneine. No other common dietary compound uses this transporter at comparable efficiency. OCTN1 is expressed at high levels in monocytes, macrophages, neutrophils, and red blood cells, and it actively pumps ergothioneine from the bloodstream into the cell interior, achieving intracellular concentrations up to 1,000 times higher than plasma.

A 2017 cardiovascular pharmacology review specifically noted OCTN1's prominent expression in monocytes and macrophages as evidence of ergothioneine's immune-protective function, documenting its protective role in vascular endothelial cells and its NF-κB suppression in the cardiovascular context.^[5]

Why does this transport distinction matter? Most antioxidants help wherever they encounter oxidative damage, distributed across all tissues in proportion to circulation. Ergothioneine concentrates precisely in the cells generating and coordinating the inflammatory response. Its anti-inflammatory effects operate at far higher local concentrations than the dietary intake levels in food would suggest. This is why ergothioneine's mechanism is better described as regulatory than scavenging: it is not cleaning up after inflammation, it is reaching the cells that are running it.

For the full biology of what happens to ergothioneine distribution during an active inflammatory event, including the evidence that blood levels drop because it is being sequestered into inflamed tissue, see OCTN1 and ergothioneine accumulation at inflammation sites. For a deep look at the transporter's discovery and substrate selectivity, see OCTN1: The Dedicated Transporter That Proves Ergothioneine Matters.

Three Inflammation Pathways Ergothioneine Shuts Down

The 2010 monocyte study demonstrated NF-κB suppression. Later research documented two additional signaling routes.

A 2025 comprehensive review of ergothioneine's mechanisms identified three distinct cytokine-producing cascades subject to dose-dependent suppression:^[3]

NF-κB is the most frequently documented target. When this protein complex activates, it migrates from the cell's fluid interior into the nucleus, where it switches on genes that produce TNF-α, IL-1β, IL-6, IL-8, and cyclooxygenase-2. Ergothioneine prevents the chemical activation step that allows NF-κB to migrate, keeping it locked out of the nucleus and those inflammatory genes unactivated.

MAPK (a cascade of kinase proteins that relays external stress signals from the cell surface to the nucleus) carries the message that triggers cytokine production. Ergothioneine interrupts this relay, reducing the downstream cytokine output.

PI3K/AKT (a two-protein signaling pair involved in cell survival and inflammation balance) promotes inflammatory mediator production when activated. Suppression by ergothioneine tilts the balance toward reduced output and supports the resolution phase of inflammation rather than sustaining it.

A 2022 review of ergothioneine's actions in central nervous system diseases confirmed the same three-pathway suppression in brain tissue, alongside Nrf2 activation, a cellular defense program that upregulates the body's own antioxidant enzymes and reduces oxidative inflammation.^[6] The 2025 review recommended 30 mg per day as the appropriate adult supplementation dose based on the available evidence.

For how ergothioneine's pathway suppression fits within the broader landscape of mushroom anti-inflammatory compounds, including the entirely separate routes taken by triterpenes and beta-glucan polysaccharides, see triterpenes vs. polysaccharides: different anti-inflammatory pathways. Ergothioneine represents a third category: not a triterpene, not a polysaccharide, but a small amino acid that accumulates in immune cells and blocks cytokine signaling at the source.

2025: A Disease Model That Shows Macrophage Repolarization

Cell culture data confirms pathways are affected. An animal disease model with quantified disease outcomes confirms whether that pathway suppression changes the course of actual pathology.

A 2025 study by Li and colleagues, published in Frontiers in Pharmacology, used an imiquimod-induced psoriasis mouse model to test ergothioneine's effects.^[2] Psoriasis is a chronic inflammatory skin disease where the immune system attacks healthy skin tissue, producing characteristic plaques. The inflammatory mechanisms are well-characterized and the endpoints are measurable: skin lesion severity, macrophage composition, cytokine levels.

The study focused on macrophage polarization. Macrophages exist on a spectrum between two functional states. M1-polarized macrophages are pro-inflammatory: they produce TNF-α, IL-6, and other amplifying signals, and they sustain the inflammatory state. M2-polarized macrophages are anti-inflammatory: they release resolution signals and support tissue repair. Chronic inflammatory diseases like psoriasis are defined in part by persistent M1 dominance.

Ergothioneine reversed this imbalance. The M1/M2 ratio shifted toward M2. The mechanism connecting the treatment to that outcome was simultaneous suppression of NF-κB phosphorylation and JAK/STAT3 activation. JAK/STAT3 is the signaling pair that maintains M1 macrophage identity: cytokines from inflamed tissue activate JAK enzymes, which in turn activate a protein called STAT3 that moves into the nucleus and switches on genes that keep macrophages in the M1 state. Ergothioneine blocked both the master switch (NF-κB) and the amplification loop (JAK/STAT3) simultaneously.

Skin lesion severity declined alongside these pathway changes.

This is the most complete in-vivo picture of how ergothioneine modulates immune cell behavior in chronic disease: pathway suppression linked to cellular outcome linked to disease outcome, all in one study. No consumer-facing resource had cited this data at time of writing. For how this macrophage mechanism connects to specific chronic diseases, see ergothioneine and chronic inflammatory conditions.

The Same Mechanism in Two More Tissues: Heart and Brain

One animal model in one tissue type could be coincidental. Replication across unrelated tissues with the same upstream target adds mechanistic weight.

In 2023, Duan and colleagues showed that ergothioneine improved cardiac function after heart attack in a mouse model by suppressing NF-κB-driven inflammatory remodeling in heart muscle.^[7] After a heart attack, NF-κB activates in surviving cardiac tissue and drives an inflammatory response. This is protective short-term, but sustained NF-κB activation leads to progressive fibrosis: scar tissue that stiffens the heart wall and reduces pumping efficiency. Ergothioneine suppressed NF-κB through S-glutathionylation, a chemical modification that prevents the protein from activating. Cardiac function improved. The downstream effector was the Wnt5a-sFlt-1 pathway, connecting NF-κB suppression to reduced scar tissue formation. This was new molecular mechanism data at time of publication.

In 2024, Chen and colleagues used an accelerated-aging mouse model to test ergothioneine's effects on neuroinflammation and cognitive function.^[8] The model is driven by D-galactose, which produces chronic brain inflammation and mitochondrial dysfunction similar to natural aging. These mice show elevated TNF-α, IL-1β, and IL-6 in brain tissue alongside measurable cognitive decline. After ergothioneine supplementation, all three cytokines declined. Mitochondrial membrane potential, which collapses under sustained oxidative inflammation, was preserved. Cognitive function recovered in maze performance tests.

The shared thread across immune cells, heart, and brain: NF-κB-driven inflammation produces tissue-specific damage, and ergothioneine suppresses the pathway upstream of that damage, before the cytokines are produced and before the organ-specific consequences cascade from them.

The Human Evidence: What Biomarkers Actually Changed

Everything above is cell culture or animal model data. The only human clinical evidence comes from a 2017 study by Cheah and colleagues, in which healthy adult volunteers received ergothioneine supplementation and were monitored for changes in blood biomarkers.^[9]

Declining trends were observed in five biomarkers:

• CRP (C-reactive protein): the standard clinical marker for systemic inflammation
• 8-iso-PGF2α: a lipid peroxidation marker reflecting oxidative damage to cell membranes
• 8-OHdG: a DNA damage marker reflecting oxidative stress reaching genetic material
• Allantoin: a marker of urate oxidation by reactive oxygen species
• Protein carbonylation: a measure of oxidative damage to proteins

This is the only published human data directly linking ergothioneine supplementation to measurable changes in inflammation and oxidative damage biomarkers.

A few important caveats. The participants were healthy adults without elevated baseline inflammation. The effects were declining trends, not dramatic clinical reductions. No result reached formal statistical significance. A trial in people with active inflammatory disease and elevated baseline CRP would tell us more about ergothioneine's clinical potential. That trial has not been published.

What this study does establish: the mechanism active in cell culture and animal models produces detectable changes in human biomarkers in the expected direction. The effect exists in humans; its clinical magnitude in disease states remains to be determined. For the full picture of what low blood ergothioneine predicts in population studies, see ergothioneine as an inflammatory biomarker.

Dietary Sources and What the Dosing Data Shows

Ergothioneine is found almost exclusively in mushrooms. Porcini, oyster, king oyster, shiitake, and maitake varieties tend to have the highest concentrations. The compound is heat-stable and concentrates further when mushrooms are dried or cooked, which is unusual for a health-active nutrient. Wild-harvested porcini typically exceed cultivated varieties by a substantial margin.

The body cannot synthesize ergothioneine. Every molecule in circulation came from the diet, and how much ends up inside immune cells depends entirely on dietary intake. Regular mushroom consumption is the only practical food-based way to build ergothioneine stores.

The dosing data from the 2017 human trial and the 2025 review points toward 25 to 30 mg per day as a working range. One 100-gram serving of cooked oyster mushrooms provides roughly 2 to 5 mg, meaning dietary intake from mushrooms alone is typically well below the studied dose range. Standalone ergothioneine supplements are available. The 2025 review noted that bioavailability from mushroom-sourced ergothioneine appears to exceed synthetic in some comparative models, though this has not been confirmed in trials focused on inflammatory endpoints.

For the COVID-19 inflammation angle, including how ergothioneine's NETosis inhibition and endothelial protection mechanisms relate to severe respiratory inflammation, see ergothioneine and COVID-19 inflammation research. For a broader introduction to ergothioneine as a compound, its chemistry, and why it is sometimes called the longevity amino acid, see what ergothioneine is and why it has a dedicated human transporter.

The Bottom Line

Ergothioneine's anti-inflammatory mechanism is unusually specific for a dietary compound: a dedicated transporter concentrates it 1,000 times higher inside immune cells than in blood, and it suppresses three master cytokine-producing switches: NF-κB, MAPK, and PI3K/AKT. This three-pathway action has been documented across human monocyte cultures, animal models of psoriasis, cardiac tissue, and aging brain. The 2025 psoriasis study linked pathway suppression to macrophage repolarization to disease outcome reduction, all in one experiment. The one human clinical study found declining trends in CRP and oxidative damage biomarkers after supplementation. No clinical trial has tested ergothioneine as a treatment for any inflammatory condition; the mechanistic evidence is strong and the human biomarker signal is real, but clinical efficacy thresholds remain undefined.

Frequently Asked Questions

Does ergothioneine reduce inflammation?

Yes. In cell culture studies and animal models, ergothioneine consistently reduces inflammatory signaling: blocking NF-κB activation in monocytes, suppressing cytokine production in cardiac and brain tissue, and repolarizing pro-inflammatory macrophages toward an anti-inflammatory state. In a human pilot study, supplementation in healthy adults produced declining trends in CRP and oxidative stress markers. No randomized controlled trial has tested ergothioneine as a treatment for an inflammatory condition.

How does ergothioneine work as an anti-inflammatory?

Ergothioneine suppresses three signaling pathways that produce pro-inflammatory cytokines: NF-κB, MAPK, and PI3K/AKT. It also shifts macrophages from the pro-inflammatory M1 state toward the anti-inflammatory M2 state, as shown in a 2025 psoriasis model. Crucially, it accumulates inside immune cells at up to 1,000 times its blood concentration via the OCTN1 transporter, placing it at its highest concentration exactly where inflammation is being orchestrated.

What is ergothioneine and what does it do?

Ergothioneine is a sulfur-containing amino acid found almost exclusively in mushrooms. The human body cannot synthesize it and depends entirely on dietary intake. The OCTN1 transporter pumps it from the bloodstream into immune cells, where it accumulates at high concentrations and suppresses inflammatory gene expression. Research documents reductions in TNF-α, IL-1β, and IL-6 production and Nrf2 activation, which upregulates the body's own antioxidant enzyme systems.

Which mushrooms are highest in ergothioneine?

Porcini mushrooms typically have the highest ergothioneine concentrations among commonly eaten varieties, followed by oyster, king oyster (Pleurotus eryngii), shiitake, and maitake. Concentrations vary by species, growing conditions, and mushroom part: stems typically contain more than caps. Ergothioneine is heat-stable and concentrates when mushrooms are dried or cooked, making preparation method less of a concern than with many other heat-sensitive nutrients.

Is ergothioneine better than other antioxidants for inflammation?

Ergothioneine is mechanistically distinct from all other dietary antioxidants in having a dedicated high-affinity transporter, OCTN1, that delivers it specifically to immune cells at concentrations up to 1,000 times higher than blood. Vitamin C, vitamin E, and polyphenols reach immune cells in proportion to blood levels with no targeting mechanism. Whether this targeted delivery translates to superior clinical anti-inflammatory outcomes compared to other antioxidants has not been tested in head-to-head human trials.

Sources & References

1. 1. Source details for this reference are not yet available.
2. 2. Source details for this reference are not yet available.
3. 3. Source details for this reference are not yet available.
4. 4. Source details for this reference are not yet available.
5. 5. Source details for this reference are not yet available.
6. 6. Source details for this reference are not yet available.
7. 7. Source details for this reference are not yet available.
8. 8. Source details for this reference are not yet available.
9. 9. Source details for this reference are not yet available.